Line 81: | Line 81: | ||
<div class="row"> | <div class="row"> | ||
<h1 class="title">Experiments</h1> | <h1 class="title">Experiments</h1> | ||
− | <h1><span>Our long-term goal is to improve the health-promoting effects of ginsenosides. We believe that sterols in the ginsenosides are responsible for their main benefits. | + | <h1><span>Our long-term goal is to improve the health-promoting effects of ginsenosides. We believe that sterols (triterpenes) in the ginsenosides are responsible for their main benefits. Therefore in the past projects we engineered synthetic squalene cyclase for in situ production of ginseng-sterols in human cells and produced synthetic β-glucosidase in E.coli for removal of sugar from ginsenosides. In the current strategy, in the wake of “No release” policy of the iGEM community, we are able to by-pass synthetic biology methods to achieve our goal by applying in vitro chemical reactions. </span></h1> |
<a href="https://static.igem.org/mediawiki/2018/e/e9/T--UST_Beijing--experiment.pdf" class="btn btn-info btn-large btn-rounded">CLICK FOR PDF</a> </div> | <a href="https://static.igem.org/mediawiki/2018/e/e9/T--UST_Beijing--experiment.pdf" class="btn btn-info btn-large btn-rounded">CLICK FOR PDF</a> </div> | ||
</div> | </div> | ||
Line 92: | Line 92: | ||
<div class="row"> | <div class="row"> | ||
<blockquote> | <blockquote> | ||
− | <p>Ginseng products offer unique opportunity to meet the atherosclerosis challenge. | + | <p>Ginseng products offer unique opportunity to meet the atherosclerosis challenge. Herbs containing ginsenosides include: Ginseng, Western Ginseng, Notoginseng, Jiaogulan etc. Current herb preparation and administration practice results in poor absorption profile limit its efficacy and cost-effectiveness. Since the ginseno-sterols are responsible for their main pharmacological effects, how to achieve effective concentration of sterol in the human body becomes critical. |
− | + | ||
− | + | ||
</p> | </p> | ||
</blockquote> | </blockquote> | ||
<blockquote> | <blockquote> | ||
− | <p>In the past, two approaches have been tried to achieve this: (1) Synthesize ginseno-sterols in situ Pro: | + | <p>In the past, two approaches have been tried to achieve this: (1) Synthesize ginseno-sterols in situ. Pro: no need to plant ginseng and harvest, continuous supply of ginseno-sterols; Con: interference with host physiology, lack of control in production. (2) Produce beta-glucosides in the gut micro-organism. Pro: convenient to hydrolyze ginsenosides in the gut; Con: interference with host gut physiology and probiotics. <br>In the current third approach, we use chemical reaction to hydrolyze the conjugated sugars, to satisfy “No-release” policy if iGEM safety requirement.</p> |
</blockquote> | </blockquote> | ||
<div class="span4"> | <div class="span4"> | ||
Line 105: | Line 103: | ||
<div class="span4" ><img src="https://static.igem.org/mediawiki/2018/3/32/T--UST_Beijing--ep14.png" heigth="70%" alt=""></div> | <div class="span4" ><img src="https://static.igem.org/mediawiki/2018/3/32/T--UST_Beijing--ep14.png" heigth="70%" alt=""></div> | ||
<h2 class="title">1. Thin—layer chromatography</h2> | <h2 class="title">1. Thin—layer chromatography</h2> | ||
− | <h3>Experimental purpose: Through | + | <h3>Experimental purpose: Through parallel experiment of different developing methods, we identified a suitable condition in TLC system to separate ginsenosides. |
− | <br>Standarded | + | <br>Standarded samples: Rb1, Re1, Rg1 10mg/ml<br>After many preliminary experiments, we try to find out a general range of proportion. Here is the last TLC experiment.</h3> |
<img src="https://static.igem.org/mediawiki/2018/e/e0/T--UST_Beijing--ep16.png" alt=""> | <img src="https://static.igem.org/mediawiki/2018/e/e0/T--UST_Beijing--ep16.png" alt=""> | ||
<h3>chromogenic agent: concentrated sulfuric acid: carbinol = 1:9<br> | <h3>chromogenic agent: concentrated sulfuric acid: carbinol = 1:9<br> | ||
− | standarded sample: extract ginsenosides from traditional Chinese medicine with | + | standarded sample: extract ginsenosides from traditional Chinese medicine with n-butanol<br> |
Result: after change the ratio of chromogenic agent,the experimental phenomenon is much more clear for observing and measuring. | Result: after change the ratio of chromogenic agent,the experimental phenomenon is much more clear for observing and measuring. | ||
</h3> | </h3> | ||
Line 115: | Line 113: | ||
<img src="https://static.igem.org/mediawiki/2018/0/0c/T--UST_Beijing--ep17.png" alt=""> | <img src="https://static.igem.org/mediawiki/2018/0/0c/T--UST_Beijing--ep17.png" alt=""> | ||
<h3>Result: it turns out when the ratio of developing agent is 10:2.5:0.25 and the ratio of chromogenic agent is 9:1,the number of Rf is relatively ideal.</h3> | <h3>Result: it turns out when the ratio of developing agent is 10:2.5:0.25 and the ratio of chromogenic agent is 9:1,the number of Rf is relatively ideal.</h3> | ||
− | <h2 class="title">2. A synthetic beta-glucosidase gene is introduced into E.coli, along with PNPG as illustrated below. The enzyme (3D structure is displayed on the left) will make a yellow color product in the medium, which is measured by spectrometry.</h2> | + | <h2 class="title">2. A synthetic beta-glucosidase gene is introduced into E.coli, which is cultured along with PNPG as illustrated below. The enzyme (3D structure is displayed on the left) will make a yellow color product in the medium, which is measured by spectrometry.</h2> |
<div class="span3"></div><img src="https://static.igem.org/mediawiki/2018/1/1c/T--UST_Beijing--ep15.png" alt=""> | <div class="span3"></div><img src="https://static.igem.org/mediawiki/2018/1/1c/T--UST_Beijing--ep15.png" alt=""> | ||
<h3><span>Experiment assignment:</span><br> | <h3><span>Experiment assignment:</span><br> |
Revision as of 14:57, 12 October 2018
Ginseng products offer unique opportunity to meet the atherosclerosis challenge. Herbs containing ginsenosides include: Ginseng, Western Ginseng, Notoginseng, Jiaogulan etc. Current herb preparation and administration practice results in poor absorption profile limit its efficacy and cost-effectiveness. Since the ginseno-sterols are responsible for their main pharmacological effects, how to achieve effective concentration of sterol in the human body becomes critical.
In the past, two approaches have been tried to achieve this: (1) Synthesize ginseno-sterols in situ. Pro: no need to plant ginseng and harvest, continuous supply of ginseno-sterols; Con: interference with host physiology, lack of control in production. (2) Produce beta-glucosides in the gut micro-organism. Pro: convenient to hydrolyze ginsenosides in the gut; Con: interference with host gut physiology and probiotics.
In the current third approach, we use chemical reaction to hydrolyze the conjugated sugars, to satisfy “No-release” policy if iGEM safety requirement.
A synthetic beta-glucosidase gene is introduced into E.coli, along with PNPG as illustrated below. The enzyme (3D structure is displayed on the left) will make a yellow color product in the medium, which is measured by spectrometry